Novel treatments for inflammatory bowel disease

키워드

참고문헌 (54)

1. Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2017)[DOI]
2. Wee Khoon Ng, "Changing epidemiological trends of inflammatory bowel disease in Asia", Intestinal research, 14(2), pp.111~119 (2016), 대한장연구학회
3. Prashant Singh, "Pivot to Asia: inflammatory bowel disease burden", Intestinal research, 15(1), pp.138~141 (2017), 대한장연구학회
4. 이강문, "Crohn’s disease in Korea: past, present, and future", The Korean Journal of Internal Medicine, 29(5), pp.558~570 (2014), 대한내과학회[DOI]
5. Burger D, "Conventional medical management of inflammatory bowel disease", Gastroenterology, 140, pp.1827~1837 (2011)[DOI]
6. Hanauer SB, "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)[DOI]
7. Sandborn WJ, "Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis", Gastroenterology, 142, pp.257~265 (2012)[DOI]
8. Sokol H, "Complications and surgery in the inflammatory bowel diseases biological era", Curr Opin Gastroenterol, 30, pp.378~384 (2014)[DOI]
9. 김남희, "Long-Term Clinical Outcomes of Korean Patient With Crohn’s Disease Following Early Use of Infliximab", Intestinal research, 12(4), pp.281~286 (2014), 대한장연구학회
10. 최창환, "Second Korean guidelines for the management of ulcerative colitis", Intestinal research, 15(1), pp.7~37 (2017), 대한장연구학회
11. 박재준, "Second Korean guidelines for the management of Crohn’s disease", Intestinal research, 15(1), pp.38~67 (2017), 대한장연구학회
12. Harbord M, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management", J Crohns Colitis, 11, pp.769~784 (2017)[DOI]
13. Gomollon F, "3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management", J Crohns Colitis, 11, pp.3~25 (2017)[DOI]
14. Allez M, "Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects", J Crohns Colitis, 4, pp.355~366 (2010)[DOI]
15. Ben-Horin S, "Review article: loss of response to anti-TNF treatments in Crohn's disease", Aliment Pharmacol Ther, 33, pp.987~995 (2011)[DOI]
16. 서현일, "The Effect of Infliximab on Patients with Ulcerative Colitis in Korea", Intestinal research, 12(3), pp.214~220 (2014), 대한장연구학회
17. Wei-Chen Lin, "Outcomes of limited period of adalimumab treatment in moderate to severe Crohn’s disease patients: Taiwan Society of Inflammatory Bowel Disease Study", Intestinal research, 15(4), pp.487~494 (2017), 대한장연구학회
18. Ford AC, "Opportunistic infections with anti-tumor necrosis factor-<TEX>$\alpha$<", TEX> therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials, 2013, pp.108, 1268~1276
19. Walsh AJ, "Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease", J Crohns Colitis, 7, pp.e449~e456 (2013)[DOI]
20. 이장욱, "Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease", Intestinal research, 14(2), pp.146~151 (2016), 대한장연구학회
21. Keun Bum Chung, "Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor", The Korean Journal of Internal Medicine, 28(2), pp.174~179 (2013), 대한내과학회[DOI]
22. Lobaton T, "Review article: anti-adhesion therapies for inflammatory bowel disease", Aliment Pharmacol Ther, 39, pp.579~594 (2014)[DOI]
23. Sandborn WJ, "Natalizumab induction and maintenance therapy for Crohn's disease", N Engl J Med, 353, pp.1912~1925 (2005)[DOI]
24. Villablanca EJ, "Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases", Gastroenterology, 140, pp.1776~1784 (2011)[DOI]
25. Bloomgren G, "Risk of natalizumab-associated progressive multifocal leukoencephalopathy", N Engl J Med, 366, pp.1870~1880 (2012)[DOI]
26. Lowenberg M, "Next-generation therapeutics for IBD", Curr Gastroenterol Rep, 17, pp.21~ (2015)[DOI]
27. Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)[DOI]
28. Sandborn WJ, "Vedolizumab as induction and maintenance therapy for Crohn's disease", N Engl J Med, 369, pp.711~721 (2013)[DOI]
29. Sands BE, "Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed", Gastroenterology, 147, pp.618~627 (2014)[DOI]
30. Colombel JF, "The safety of vedolizumab for ulcerative colitis and Crohn's disease", Gut, 66, pp.839~851 (2017)[DOI]
31. Vermeire S, "Long-term efficacy of vedolizumab for Crohn's disease", J Crohns Colitis, 11, pp.412~424 (2017)
32. Loftus EV Jr, "Long-term efficacy of vedolizumab for ulcerative colitis", J Crohns Colitis, 11, pp.400~411 (2017)
33. Cepek KL, "Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells", J Immunol, 150(8), pp.3459~3470 (1993)
34. Vermeire S, "Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial", Lancet, 384, pp.309~318 (2014)[DOI]
35. Vermeire S, "The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study", Gut, 60, pp.1068~1075 (2011)[DOI]
36. Vermeire S, "Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial", Lancet, 390, pp.135~144 (2017)[DOI]
37. D'Haens G, "OP022 Anti-MAd-CAM-1 antibody (PF-00547659) for active refractory Crohn's disease: results of the OPERA study", 10th Congress of European Crohn's and Colitis Organisation (ECCO), pp.S14~ (2015), ECCO
38. Lundquist LM, "Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis", World J Orthop, 5, pp.504~511 (2014)[DOI]
39. Vijayakrishnan L, "Treating inflammation with the Janus kinase inhibitor CP-690,550", Trends Pharmacol Sci, 32, pp.25~34 (2011)[DOI]
40. Sandborn WJ, "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis", N Engl J Med, 367, pp.616~624 (2012)[DOI]
41. Sandborn WJ, "Ozanimod induction and maintenance treatment for ulcerative colitis", N Engl J Med, 374, pp.1754~1762 (2016)[DOI]
42. D'Haens GR, "856 Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn's disease: results of a phase 2B randomized placebo-controlled trial", Gastroenterology, 150(4 Suppl 1), pp.S183~ (2016)
43. Sandborn WJ, "A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease", Clin Gastroenterol Hepatol, 12, pp.1485~1493 (2014)[DOI]
44. Panes J, "855 Efficacy and safety of tofacitinib for oral induction therapy in patients with moderate to severe Crohn's disease: results of a phase 2B randomized placebo-controlled trial", Gastroenterology, 150(4 Suppl 1), pp.S182~S183 (2016)
45. Di Sabatino A, "Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures", Gut, 58, pp.777~789 (2009)[DOI]
46. Marafini I, "TGF-beta signaling manipulation as potential therapy for IBD", Curr Drug Targets, 14, pp.1400~1404 (2013)[DOI]
47. Kennedy BW, "Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease", N Engl J Med, 372, pp.2461~ (2015)[DOI]
48. Leonardi CL, "Efficacy and safety of ustekinumab, a human interleukin-12", 23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), 2008, pp.371, 1665~1674
49. Papp KA, "Efficacy and safety of ustekinumab, a human interleukin-12", 23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), 2008, pp.371, 1675~1684
50. Sandborn WJ, "A randomized trial of ustekinumab, a human interleukin-12", 23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease, 2008, pp.135, 1130~1141
51. Sandborn WJ, "Ustekinumab induction and maintenance therapy in refractory Crohn's disease", N Engl J Med, 367, pp.1519~1528 (2012)[DOI]
52. Toshifumi Hibi, "Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies", Intestinal research, 15(4), pp.475~486 (2017), 대한장연구학회
53. Sanchez T, "Structural and functional characteristics of S1P receptors", J Cell Biochem, 92, pp.913~922 (2004)[DOI]
54. Narula N, "Novel therapies in inflammatory bowel disease: an evaluation of the evidence", Am J Gastroenterol Suppl, 3, pp.38~44 (2016)[DOI]

관련 논문AI추천